Molecular Partners

Molecular Partners Debt

The Debt of Molecular Partners (MOLN.SW) as of Nov 19, 2026 is 3.64 M CHF. In the previous year, Debt was 2.44 M CHF — a change of 49.10% (higher).

Debt

3.64 MCHF

YoY

49.10%

Last updated:

In 2025, Molecular Partners's total debt was 3.64 M CHF, a 49.10% change from the 2.44 M CHF total debt recorded in the previous year.

The Molecular Partners Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 CHF
Jan 1, 2019
2.55 M CHF
Jan 1, 2020
7.22 M CHF
Jan 1, 2021
6.04 M CHF
Jan 1, 2022
4.85 M CHF
Jan 1, 2023
3.65 M CHF
Jan 1, 2024
2.44 M CHF
Jan 1, 2025
3.64 M CHF
The Molecular Partners Debt history
YEARDebtYoY
3.64 MCHF+49.10%
2.44 MCHF-33.08%
3.65 MCHF-24.70%
4.85 MCHF-19.69%
6.04 MCHF-16.33%
7.22 MCHF+183.61%
2.55 MCHF—
0.00CHF—
0.00CHF—
0.00CHF—
0.00CHF—
0.00CHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Molecular Partners Stock analysis

What does Molecular Partners do? Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.

Debt Details

Understanding Molecular Partners's Debt Structure

Molecular Partners's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Molecular Partners's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Molecular Partners’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Molecular Partners’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Molecular Partners stock

Debt of Molecular Partners is 3.64 M CHF in 2025.

Debt of Molecular Partners changed from 2.44 M CHF to 3.64 M CHF, representing a 49.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Molecular Partners since 2006 – with annual values, charts, and detailed analysis.

Debt's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Molecular Partners historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Molecular Partners

All Key Metrics — Molecular Partners